On June 25, Spyre Therapeutics fell 5.04% in pre-market trading, trading at $82.44/share, with turnover of $18,000. The stock continues to face selling pressure following a sharp 13%-plus decline in the prior session.

On the news front, a regulatory filing disclosed that director Michael Thomas Henderson sold 20,000 company shares on June 22 for approximately $2 million. Since the disclosure on June 23, the stock has come under sustained pressure, with trading volume in the prior session surging to over 2.9 million shares — more than double the daily average of roughly 1.3 million. For a clinical-stage biotechnology company still operating at a loss with negative earnings per share of -$0.74 as of its most recent quarterly report, insider selling has amplified market concerns about the company's outlook.

Spyre Therapeutics is a preclinical-stage biotechnology company focused on developing therapeutics for inflammatory bowel disease, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)